Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
复制标题
DOI：
10.1055/s-0043-112346
复制
发表时间：
2017-08-01
影响因子：
2.2
通讯作者：
Asemi, Zatollah
中科院分区：
文献类型：
--
作者：
Foroozanfard, Fatemeh;Talebi, Maesoomeh;Asemi, Zatollah
本研究旨在评价两种不同剂量的维生素D补充剂对胰岛素抵抗的多囊卵巢综合征（PCOS）患者代谢特征的影响。这项随机、双盲、安慰剂对照试验在90例符合鹿特丹标准的胰岛素抵抗PCOS患者中进行，年龄18 - 40岁。受试者被随机分为3组，分别接受4 000 IU维生素D（n = 30）或1 000 IU维生素D（n = 30）或安慰剂（n = 30），每天12周。补充维生素d（4 000 IU），与维生素D相比（1000 IU）和安慰剂，导致空腹血糖降低（分别为-4.3 +/-8.6 vs.-4.7 +/-7.1和+0.1 +/-6.7 mg/dl，p = 0.02），血清胰岛素浓度（分别为-2.7 +/-2.7 vs.-1.4 +/-4.2和-0.1 +/-4.1 mu IU/ml，p = 0.02）和HOMA-IR（分别为-0.6 +/-0.6对比-0.4 +/-1.0和-0.1 +/-0.9，p = 0.02）。此外，我们发现血清甘油三酯的平均变化显著降低，（分别为-10.3 +/-7.3 vs.-3.6 +/-14.5和+6.9 +/-23.8 mg/dl，p = 0.001），VLDL-（分别为-2.0 +/-1.5 vs.-0.7 +/-2.9和+1.4 +/-4.8 mg/dl，p = 0.001），总-（分别为-14.0 +/-9.5 vs.-6.2 +/-24.0和+7.1 +/-29.7 mg/dl，p = 0.002），LDL（分别为-10.8 +/-8.3 vs.-5.7 +/-21.9和+6.8 +/-28.2 mg/dl，p = 0.005）和总胆固醇/HDL-胆固醇比值高剂量维生素D组与低剂量维生素D组和安慰剂组相比（分别为-0.2 +/-0.3 vs.-0.1 +/-0.6和+0.2 +/-0.7 mg/dl，p = 0.003）。总的来说，与每天补充1 000 IU维生素D和安慰剂组相比，每天补充4 000 IU维生素D 12周对胰岛素抵抗的PCOS患者的葡萄糖代谢和血脂具有有益作用。
The current study was conducted to evaluate the effects of 2 different doses of vitamin D supplementation on metabolic profiles of insulin-resistant patients with polycystic ovary syndrome (PCOS). This randomized double-blind, placebo-controlled trial was performed on 90 insulin-resistant patients with PCOS according to the Rotterdam criteria aged 18-40 years old. Participants were randomly allocated into 3 groups to receive either 4 000 IU of vitamin D (n = 30) or 1 000 IU of vitamin D (n = 30) or placebo (n = 30) per day for 12 weeks. Vitamin D supplementation (4 000 IU), compared with vitamin D (1 000 IU) and placebo, led to reduced fasting plasma glucose (-4.3 +/- 8.6 vs. -4.7 +/- 7.1 and +0.1 +/- 6.7 mg/dl, respectively, p = 0.02), serum insulin concentrations (-2.7 +/- 2.7 vs. -1.4 +/- 4.2 and -0.1 +/- 4.1 mu IU/ml, respectively, p = 0.02), and HOMA-IR (-0.6 +/- 0.6 vs. -0.4 +/- 1.0 and -0.1 +/- 0.9, respectively, p = 0.02). In addition, we found significant decreases in mean change of serum triglycerides (-10.3 +/- 7.3 vs. -3.6 +/- 14.5 and + 6.9 +/- 23.8 mg/dl, respectively, p = 0.001), VLDL-(-2.0 +/- 1.5 vs. -0.7 +/- 2.9 and + 1.4 +/- 4.8 mg/dl, respectively, p = 0.001), total-(-14.0 +/- 9.5 vs. -6.2 +/- 24.0 and + 7.1 +/- 29.7 mg/dl, respectively, p = 0.002), LDL(-10.8 +/- 8.3 vs. -5.7 +/- 21.9 and + 6.8 +/- 28.2 mg/dl, respectively, p = 0.005), and total-/HDL-cholesterol ratio (-0.2 +/- 0.3 vs. -0.1 +/- 0.6 and + 0.2 +/- 0.7 mg/dl, respectively, p = 0.003) in the high-dose vitamin D group compared with low-dose vitamin D and placebo groups. Overall, vitamin D supplementation at a dosage of 4 000 IU/day for 12 weeks in insulin-resistant patients with PCOS had beneficial effects of glucose metabolism and lipid profiles compared with 1 000 IU/day of vitamin D and placebo groups.